Brainstorm Cell Therapeutics Inc
BCLI1.170USD
-0.030-2.50%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
9.26MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Brainstorm Cell Therapeutics Inc Unternehmen
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Unternehmensinformationen
BörsenkürzelBCLI
Name des UnternehmensBrainstorm Cell Therapeutics Inc
IPO-datumMay 28, 2003
CEOMr. Chaim Lebovits
Anzahl der mitarbeiter27
WertpapierartOrdinary Share
GeschäftsjahresendeMay 28
Addresse1325 Avenue Of Americas
StadtNEW YORK
BörseUS 'Other OTC' and Grey Market
LandUnited States of America
Postleitzahl10019
Telefon12014880460
Websitehttps://brainstorm-cell.com/
BörsenkürzelBCLI
IPO-datumMay 28, 2003
CEOMr. Chaim Lebovits
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+919.54%
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+3833.25%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sun, Jul 27
Aktualisiert: Sun, Jul 27
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
Aktionäre
Aktionäre
Anteil
Armistice Capital LLC
8.70%
Ruck (Matthew J)
3.47%
Ness (Kevin Dean)
2.57%
Lebovits Chaim
2.53%
Caldwell Sutter Capital, Inc
1.98%
Other
80.75%
Aktionärstypen
Aktionäre
Anteil
Individual Investor
14.30%
Hedge Fund
9.03%
Investment Advisor
3.58%
Holding Company
1.68%
Investment Advisor/Hedge Fund
0.73%
Research Firm
0.04%
Other
70.63%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
115
2.33M
29.37%
+771.43K
2025Q1
116
2.29M
28.90%
+743.86K
2024Q4
114
1.19M
21.02%
-226.10K
2024Q3
109
1.22M
22.61%
-265.31K
2024Q2
109
1.32M
25.54%
+439.02K
2024Q1
108
855.32K
19.26%
-132.87K
2023Q4
109
841.70K
26.44%
-125.02K
2023Q3
116
902.82K
33.14%
-178.28K
2023Q2
123
1.03M
39.20%
+17.38K
2023Q1
150
979.29K
38.21%
+5.81K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Armistice Capital LLC
690.67K
8.7%
+690.67K
--
Mar 31, 2025
Ruck (Matthew J)
275.84K
3.47%
+275.84K
--
Nov 13, 2024
Ness (Kevin Dean)
204.00K
2.57%
-40.00K
-16.39%
Feb 14, 2024
Lebovits Chaim
200.96K
2.53%
--
--
Apr 01, 2025
Caldwell Sutter Capital, Inc
157.01K
1.98%
--
--
Mar 31, 2025
ACC International Holdings, Ltd.
133.39K
1.68%
--
--
Apr 01, 2025
Dagher (Ibrahim B.)
79.52K
1%
--
--
Apr 01, 2025
Yablonka (Uri)
68.46K
0.86%
--
--
Apr 01, 2025
Geode Capital Management, L.L.C.
58.16K
0.73%
+5.66K
+10.79%
Mar 31, 2025
Hartounian (Hartoun)
52.00K
0.66%
--
--
Apr 01, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Datum
Art
Verhältnis
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
Sep 26, 2024
Merger
15<1
